Global Rheumatoid Arthritis Industry

1
PharmaPoint Rheumatoid Arthritis Global Drug
Forecast and Market Analysis Event-Driven
Updateby GlobalData

• Explore all reports for Arthritis Drugs market
  
• _at_
• http//www.rnrmarketresearch.com/reports/life-scie
  nces/pharmaceuticals/diseases-treatment/arthritis-
  drugs

2
PharmaPoint Rheumatoid Arthritis Global Drug
Forecast and Market Analysis Event-Driven Update

• The collection of Arthritis Drugs market
  research reports has a new addition of
  PharmaPoint Rheumatoid Arthritis Global Drug
  Forecast and Market Analysis Event-Driven Update
  on RnRMarketResearch.com. PharmaPoint
  Rheumatoid Arthritis Global Drug Forecast and
  Market Analysis Event-Driven Update. The RA
  market is currently very dynamic, with the
  November 6, 2012 FDA approval of Pfizers Xeljanz
  (tofacitinib) and novel oral therapies awaiting
  approval such as Eli Lillys anti-BAFF,
  tabalumab and JAK1,2 inhibitor, baricitinib, and
  Rigel/AZs SYK inhibitor, fostamatinib. These
  compounds will challenge the current biologics in
  the attempt to dislodge the stronghold of the TNF
  inhibitors, if their safety and efficacy profiles
  are proven once they enter the market.
• Highlights
• About the Report
• The report is an essential source of information
  and analysis on the global RA market.
• Request a Sample Copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname150342 .

3
PharmaPoint Rheumatoid Arthritis Global Drug
Forecast and Market Analysis Event-Driven Update

• The report identifies the key trends shaping and
  driving the global RA market, and provides
  insight on the prevalent competitive landscape
  and the emerging players expected to
  significantly alter the market positioning of the
  existing market leaders. In addition, the report
  provides valuable insights on the pipeline
  products within the global RA market.
• Key Questions Answered
• How will the patent expiry of Enbrel and Humira
  affect the competitive landscape?
• When will biosimilars emerge and how will they
  affect the market?
• What effect have changing regulations had on
  companies investing in the sector?
• Who is the frontrunner in the drug pipeline for
  RA and what are its strengths and weaknesses?
• Complete Report is Available _at_ http//www.rnrmarke
  tresearch.com/pharmapoint-rheumatoid-arthritis-glo
  bal-drug-forecast-and-market-analysis-event-driven
  -update-market-report.html

4
PharmaPoint Rheumatoid Arthritis Global Drug
Forecast and Market Analysis Event-Driven Update

• Key Findings
• The global RA therapeutics market is forecast to
  reach 21 billion by 2022 due to the launch of
  novel pipeline drugs and biosimilars.
• The RA pipeline is strong, with 46 molecules in
  Phase II-III, including 4 first-in-class
  molecules, 2 me-too products, 7 biosimilar
  molecules.
• By 2022, RA will be a crowded marketplace
  comprising a highly diversified field of
  therapies with individual drugs struggling to
  distinguish themselves
• Pfizer/Amgen and Abbott are leading companies in
  the current competitive landscape. However,
  neither Amgen nor Abbott has any phase III
  candidates for RA therapy, indicating that a new
  competitive landscape is likely to emerge.
• Key Benefits
• Develop business strategies by understanding the
  trends shaping and driving the global RA
  therapeutics market.
• Request a Sample Copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname150342 .

5
PharmaPoint Rheumatoid Arthritis Global Drug
Forecast and Market Analysis Event-Driven Update

• Drive revenues by understanding the key trends,
  innovative products and technologies, market
  segments, and companies likely to impact the
  global RA therapeutics market in future.
• Formulate effective sales and marketing
  strategies by understanding the competitive
  landscape and by analyzing the performance of
  various competitors.
• Identify emerging players with potentially strong
  product portfolios and create effective
  counter-strategies to gain a competitive
  advantage.
• Track drug sales in the global RA therapeutics
  market from 2012-2022.
• Organize your sales and marketing efforts by
  identifying the market categories and segments
  that present
• Scope
• Overview of RA, including epidemiology, etiology,
  symptoms, diagnosis, pathology and treatment
  guidelines.
• Complete Report is Available _at_ http//www.rnrmarke
  tresearch.com/pharmapoint-rheumatoid-arthritis-glo
  bal-drug-forecast-and-market-analysis-event-driven
  -update-market-report.html

6
PharmaPoint Rheumatoid Arthritis Global Drug
Forecast and Market Analysis Event-Driven Update

• Analysis of the current and future market
  competition in the global RA therapeutics market,
  including up-to-date information on the recent
  approval of Pfizers Xeljanz (tofacitinib).
• Pipeline analysis comprehensive data split
  across Phase II-III, emerging trends and
  mechanisms of action under development,
  including Oral kinase inhibitors Janus Kinase
  (JAK), Spleen Tyrosine Kinase (SYK) inhibitors,
  c-Kit (tyrosine kinase inhibitor), anti-BAFF (B
  cell activating factor), therapeutic vaccine,
  IL-6 and IL-17 inhibitors.
• Annualized RA therapeutics market forecast,
  annual cost of therapy and treatment usage
  pattern data from 2011-2022.
• Insightful review of the key industry drivers,
  restraints and challenges. Each trend is
  independently researched to provide qualitative
  analysis of its implications.
• Key topics covered include strategic competitor
  assessment, pipeline assessment, market outlook,
  current and future players, disease management,
  unmet needs for the RA therapeutics market
• Request a Sample Copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname150342 .

7
PharmaPoint Rheumatoid Arthritis Global Drug
Forecast and Market Analysis Event-Driven Update

• Reasons to buy
• Develop business strategies and perform superior
  market quantification analysis by -
• Understanding the trends shaping and driving the
  global Rheumatoid Arthritis Therapeutics market.
• Understanding treatment preferences of physicians
  in disease state and across treatment flow.
• Accessing market sizing, forecasts and quantified
  growth opportunities in the global Rheumatoid
  Arthritis Therapeutics market till 2022.
• Quantifying patient population in the global
  Rheumatoid Arthritis Therapeutics market to
  better design product pricing launch plans.
• Drive revenues, formulate effective sales and
  marketing strategies and gain in-depth
  understanding of the competitive landscape by
• Performing benchmarking analysis and growth
  opportunities against currently marketed
  products.
• Complete Report is Available _at_ http//www.rnrmarke
  tresearch.com/pharmapoint-rheumatoid-arthritis-glo
  bal-drug-forecast-and-market-analysis-event-driven
  -update-market-report.html

8
PharmaPoint Rheumatoid Arthritis Global Drug
Forecast and Market Analysis Event-Driven Update

• For more details contact Mr. Priyank Tiwari
  sales_at_rnrmarketresearch.com / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.